MAX Chat
Company Analysis Takeda Pharmaceutical Company Limited
1. Summary
Advantages
- Price (28.27 $) is less than fair price (36.53 $)
- Dividends (8.93%) are higher than the sector average (2.28%).
- The stock's return over the last year (-0.6816%) is higher than the sector average (-3.67%).
- Current debt level 36.16% is below 100% and has decreased over 5 years from 41.46%.
Disadvantages
- The company's current efficiency (ROE=2.11%) is lower than the sector average (ROE=12.46%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Takeda Pharmaceutical Company Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | -3.8% | -7.9% | 0.5% |
| 90 days | 8.2% | -8.9% | 18.9% |
| 1 year | -0.7% | -3.7% | 13.6% |
TKPHF vs Sector: Takeda Pharmaceutical Company Limited has outperformed the "Healthcare" sector by 2.99% over the past year.
TKPHF vs Market: Takeda Pharmaceutical Company Limited has significantly underperformed the market by -14.32% over the past year.
Stable price: TKPHF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: TKPHF with weekly volatility of -0.0131% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (28.27 $) is lower than the fair price (36.53 $).
Price significantly below the fair price: The current price (28.27 $) is 29.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (47.25) is lower than that of the sector as a whole (54.24).
P/E vs Market: The company's P/E (47.25) is lower than that of the market as a whole (59.87).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.9359) is lower than that of the sector as a whole (4.2).
P/BV vs Market: The company's P/BV (0.9359) is lower than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.6) is lower than that of the sector as a whole (4.62).
P/S vs Market: The company's P/S indicator (1.6) is lower than that of the market as a whole (3.43).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (12.43) is lower than that of the sector as a whole (14.71).
EV/Ebitda vs Market: The company's EV/Ebitda (12.43) is lower than that of the market as a whole (40.12).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 45.13% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (45.13%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0.5351%).
5.4. ROE
ROE vs Sector: The company's ROE (2.11%) is lower than that of the sector as a whole (12.46%).
ROE vs Market: The company's ROE (2.11%) is lower than that of the market as a whole (41.73%).
5.5. ROA
ROA vs Sector: The company's ROA (0.9913%) is lower than that of the sector as a whole (6.23%).
ROA vs Market: The company's ROA (0.9913%) is lower than that of the market as a whole (29.55%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (5.63%) is lower than that of the sector as a whole (15.34%).
ROIC vs Market: The company's ROIC (5.63%) is lower than that of the market as a whole (10.99%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 8.93% is higher than the average for the sector '2.28%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 8.93% has been steadily paid over the past 7 years, DSI=0.71.
Weak dividend growth: The company's dividend yield 8.93% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (199.34%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
